^
Association details:
| Biomarker: | CARD11 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug Class: | BTK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
2454 Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas
Published date:
11/04/2020
Excerpt:
CTX-177 was efficacious against ABC-DLBCL and MCL models in vitro and in vivo....In addition, the MALT1 inhibitor showed an anti-tumor effect against CARD11 mutated ABC-DLBCL model, which is resistant to BTK inhibitor.
